VAGELOS P ROY 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Apr 1, 2022
Insider Transaction Report
Form 4
VAGELOS P ROY
Director
Transactions
- Sale
Common Stock
2022-03-30$700.00/sh−14,286$10,000,200→ 23,461 total(indirect: By Trust) - Sale
Common Stock
2022-03-30$700.02/sh−14,286$10,000,486→ 127,006 total(indirect: by CLAT)
Holdings
- 3,609(indirect: By Trust)
Common Stock
- 345,566
Common Stock
- 2,096(indirect: By 401(k))
Common Stock
Footnotes (4)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- [F2]Represents volume-weighted average price of sales of 14,286 shares of Company stock on March 30, 2022 at prices ranging from $700.00 to $700.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 30, 2022 at each separate price.
- [F3]Represents volume-weighted average price of sales of 14,286 shares of Company stock on March 30, 2022 at prices ranging from $700.00 to $700.05. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 30, 2022 at each separate price.
- [F4]By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.